Medisun Precision Medicine Ltd. (fka MPME)

[Roland Rick Perry]

The Chances of Surviving Brain Cancer are Minimal.

Just came across a great article on Dr. Henry Brem (from 2005), Director of the Department of Neurosurgery, and Neurosurgeon-in-Chief at The Johns Hopkins University.

Accurexa (ACXA) recently announced it had entered into an exclusive license agreement which allows the company to collaborate with Prof. Brem's outstanding team at Johns Hopkins University - with regards to a composition for treating an individual with a solid tumor comprising a combination of BCNU and temozolomide.

BCNU (carmustine) is a chemotherapy drug that is contained in Gliadel(R), a biodegradable polymer that is implanted locally into the resection cavity after surgical removal of a brain tumor and is indicated for the treatment of newly diagnosed and recurrent GBM.

Temozolomide is a now a generic, approved chemotherapy drug that is indicated for the treatment of glioblastoma multiforme (GBM). Before temozolomide became generic, it generated US sales of $420 million and global sales of $910 million under its brand name Temodar(R) in 2012.

The first glimpse I had of Dr. Henry Brem has stuck with me.

It was in 1987, well before he'd become head of neurosurgery at Johns Hopkins. As a media specialist for Hopkins, I was wedged into a corner of an elevator, watching a man I presumed was Brem on his way to a press conference. He was talking about how he had been placing therapeutic wafers of some sort into the brains of tumor patients. I remember less about the science than Brem's demeanor. Though his voice was soft, it was excited and genuine. He radiated an optimism that left us mesmerized as the doors opened. An E.F. Hutton moment. We'd have bought stock in his technique that afternoon, had it existed.

FULL ARTICLE:

http://biotechstockreview.ning.com/profiles/blogs/the-chances-of-surviving-brain-cancer-are-minimal